Neogene Therapeutics
About Neogene Therapeutics
Neogene Therapeutics is a global, preclinical stage biotechnology company pioneering the development of next generation, fully individualized engineered T cell therapies for a broad spectrum of cancers.
Our proprietary neoantigen T cell receptor (TCR) discovery and T cell engineering platform identifies TCR genes with specificity for neoantigens – found exclusively on cancer cells as a result of cancer-associated DNA mutations.
Cancer is a genetically individual disease – no two tumors are exactly the same. These variations create neoantigens – unique targets for every tumor. Neogene’s novel approach delivers a tailored T cell therapy containing a unique set of specific TCR genes for each individual patient. Engineered into patient-derived T cells, these TCRs are directed toward neoantigens in tumor cells, with the goal of eliciting strong and durable responses in a variety of solid tumor indications.
We offer the opportunity to join a highly dynamic biotech start-up. You can expect a collaborative environment created by a team with deep scientific expertise and an industrial track-record in T cell therapies. We value pro-active team-players who pursue their goals with dedication, endurance and a daring mindset. If you share our commitment to make a difference to patients in need, we can provide an exciting opportunity for your career.
14 articles with Neogene Therapeutics
-
AstraZeneca to Acquire Neogene Therapeutics, Accelerating Ambition in Oncology Cell Therapy
11/29/2022
Neogene Therapeutics, Inc., a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies, announced it has entered into a definitive agreement to be acquired by AstraZeneca.
-
AstraZeneca and Neogene have entered into a definitive acquisition agreement in which AstraZeneca will buy all outstanding equity in the smaller company.
-
Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio's pediatric methylmalonic acidemia study is back up and running and another look at Roche's TIGIT flop.
-
Neogene Therapeutics Announces Approval of Clinical Trial Application for its First Phase 1 Trial of Novel, Fully-Individualized TCR Therapy to Treat Advanced Solid Tumors
5/10/2022
Neogene Therapeutics, Inc. today announced the approval of the company’s first Clinical Trial Application (CTA) by the Dutch regulatory authority for a Phase 1 study of NT-125, an autologous, fully-individualized, multi-specific TCR therapy for the treatment of advanced solid tumors.
-
Neogene Therapeutics Announces Exclusive License with the National Cancer Institute for a Portfolio of T Cell Receptors (TCR) Targeting KRAS and TP53 Mutations for the Treatment of Cancer
1/11/2022
Neogene Therapeutics, Inc. today announced an exclusive, worldwide license agreement with the National Cancer Institute (NCI) for a portfolio of TCRs targeting KRAS and TP53 mutations for the treatment of patients with cancer.
-
BioSpace Movers & Shakers, Dec. 24
12/24/2021
With all eyes on a new year, life sciences companies and organizations are making last-minute appointments to strengthen their leadership teams and board with these Movers & Shakers. -
Neogene Therapeutics Appoints Raphaël Rousseau, M.D., Ph.D., as Chief Medical Officer
12/16/2021
Neogene Therapeutics, Inc. today announced the appointment of Raphaël Rousseau, M.D., Ph.D. as Chief Medical Officer.
-
It is the largest venture capital fund in Europe focused on the life sciences.
-
Neogene Therapeutics Appoints Han Lee, Ph.D., MBA, as Chief Financial Officer
9/14/2021
Neogene Therapeutics, Inc. today announced the appointment of Han Lee, Ph.D., MBA, as its Chief Financial Officer.
-
Vida Ventures III will approach investments the same way its first two funds do, identifying and investing in what they believe to be transformative biomedical innovative companies.
-
The new U.S. HQ for Neogene has the backing of biotech guru Arie Belldegrun, CEO of Kite Pharma. The company has leased 38,000 sq. ft. in two Santa Monica buildings.
-
BioSpace Movers & Shakers, May 28
5/28/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Neogene Therapeutics Announces Ton Schumacher, Ph.D., Company Co-Founder, Awarded 2021 Jeantet-Collen Prize for Translational Medicine
1/26/2021
Renowned immunologist and T cell engineering expert awarded distinguished prize for conducting fundamental translational research of substantial significance for medicine
-
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.